21 Dec, 2023 Our predictions for life sciences in 2024 By DLA Piper Life Sciences As the New Year is fast approaching, we asked members of our international Life Sciences team to share their predictions of what will be...
23 Nov, 2023 UK CMA publishes Competition Law Guidance for Cooperations on Combination Therapies By Alexandra Kamerling Executive Summary Combination therapies involve the use of two or more separate medicines in combination to treat a disease. It can be...
06 Nov, 2023 The EU Foreign Subsidies Regulation - life sciences companies impacted by EC review of transactions and public procurement By Joost Haans Anna Sacco On 12 October 2023, EU Foreign Subsidies Regulation (“FSR”) filings to the European Commission (“EC”) became mandatory. In addition to...
29 May, 2023 EU Pharma Law Forum 2023 - competition highlights By Joost Haans On 23 May 2023, Joost Haans from our Life Sciences team attended the EU Pharma Law Forum in Brussels where he participated in the...
06 Jul, 2022 Life Sciences update for Ireland: Watch out for major changes to the competition rules By Darach Connolly On 29 June 2022, Ireland enacted major reforms to its Competition Act. These changes could have a significant impact across most sectors...
03 Jun, 2021 Learning the Lessons on Excessive Pricing from Aspen By Darach Connolly Richard Jenkinson Daniel Wojtczak Alina Lacatus +1 more... Show less Back in April 2017, The Times ran a story detailing how a drug giant had a “secret plan” to destroy a cancer medicine unless large price...
22 Feb, 2021 Proposed Reform to the UK's NHS Procurement Regime By Hannah Gardiner On 11 February 2021, the Department of Health and Social Care published a white paper - Integration and innovation: working together to...
15 Feb, 2021 The European Commission accepts commitments by Aspen to reduce prices for six off-patent cancer medicines By Vadim Barbu The European Commission has accepted commitments by Aspen to reduce the price of six critical, off-patent, cancer medicines by 73% on...